Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Debt / NOTE 4.000% 2/0
-
Market price (% of par)
-
100.0%
-
Total 13F principal
-
$118,816,000
-
Principal change
-
+$1,246,987
-
Total reported market value
-
$118,561,560
-
Number of holders
-
16
-
Value change
-
+$1,246,153
-
Number of buys
-
7
-
Number of sells
-
7
Institutional Holders of PDL BIOPHARMA INC - NOTE 4.000% 2/0 as of Q4 2017
As of 31 Dec 2017,
PDL BIOPHARMA INC - NOTE 4.000% 2/0 was held by
16 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$118,816,000
in principal (par value) of the bond.
The largest 10 bondholders included
ASCEND CAPITAL, LLC, UBS ASSET MANAGEMENT AMERICAS INC, Radcliffe Capital Management, L.P., OAKTREE CAPITAL MANAGEMENT LP, COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS, ZAZOVE ASSOCIATES LLC, Bank of New York Mellon Corp, Russell Investments Group, Ltd., ADVENT CAPITAL MANAGEMENT /DE/, and MORGAN STANLEY.
This page lists
16
institutional bondholders reporting positions
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.